GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Inhibrx Biosciences
Following the spinoff of its oncology business, Inhibrx shares represent a bet on its remaining drugs, particularly those for the treatment of rare genetic diseases. The price trajectory depends on the results of clinical trials and the potential of these drugs.
Share prices of companies in the market segment - General oncology therapy
Inhibrx Biosciences develops antibodies for the treatment of cancer and rare diseases, creating new therapeutic approaches. We've classified the company in the "General Oncology Therapy" segment, which encompasses developers of a wide range of anti-cancer drugs. The chart below shows the overall dynamics of this biotech sector, allowing us to gauge investor sentiment.
Broad Market Index - GURU.Markets
Inhibrx is a biopharmaceutical company developing a new class of protein therapeutics for the treatment of oncology and rare diseases. As a component of the GURU.Markets index, it represents the biotech sector. The chart below represents the entire market. See how Inhibrx shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
INBX - Daily change in the company's share price Inhibrx Biosciences
The volatility of Inhibrx, a biopharmaceutical company, reflects the high risks of the biotech sector. Change_co is an immediate reaction to news about clinical trials of its protein therapies. This metric is the basis for analysis of the innovative drug development sector on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - General oncology therapy
Inhibrx Biosciences Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with INBX's performance, which is dependent on clinical trial results, helps assess it as a high-risk asset compared to more diversified companies.
Daily change in the price of a broad market stock, index - GURU.Markets
Inhibrx is a biopharmaceutical company developing drugs to treat various diseases. The biotech sector is known for its high volatility. The chart below shows average daily fluctuations in the industry, allowing one to assess how Inhibrx's performance compares to overall trends.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Inhibrx Biosciences
Inhibrx Biosciences' year-to-date performance is a story of developing a new generation of targeted biologics. Its market capitalization fluctuates dramatically over the past 12 months based on clinical trial data for its lead candidates. The successful sale of one of its assets to a major pharmaceutical company was a fundamental event, confirming the value of its scientific platform.
Annual dynamics of market capitalization of the market segment - General oncology therapy
Inhibrx, Inc. is a clinical-stage biotech company developing a new class of biologic drugs. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs inherent in the biotech sector compared to big pharma.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Inhibrx is a clinical-stage biotech whose fate since its IPO has depended on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Inhibrx Biosciences
As a biopharmaceutical company, Inhibrx's performance will be speculative. Monthly fluctuations on the chart will reflect not revenue, but rather news about the progress of its innovative drugs' clinical trials, the success of which will determine its entire future valuation.
Monthly dynamics of market capitalization of the market segment - General oncology therapy
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing a new class of biological therapeutics for the treatment of oncology and rare diseases. Its sector dynamics, shown in the chart, reflect the high risks of R&D. Against this backdrop, one can assess how its unique scientific platform and clinical progress impact its valuation.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Inhibrx is a biotech company whose stock moves in response to progress in oncology drug development. Its dynamics are weakly correlated with the market. The chart clearly shows that monthly price fluctuations reflect news about clinical trials rather than a reaction to macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Inhibrx Biosciences
Inhibrx is a biopharmaceutical company with a broad pipeline of developments in oncology and rare disease treatments. Its weekly stock price reflects expectations for its various clinical programs, making it volatile but potentially diversified.
Weekly dynamics of market capitalization of the market segment - General oncology therapy
Inhibrx, like the entire biotech sector, is extremely volatile. Weekly stock price fluctuations in this segment often reflect general scientific breakthroughs or setbacks that impact investor interest in the entire sector. The chart shows how the company is tracking this general biotech trend.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Inhibrx Biosciences is another biotech company whose stock exists in its own universe, reacting to clinical trial data. The chart clearly demonstrates how its weekly performance is isolated from general market fluctuations, following its own unique scientific trajectory.
Market capitalization of the company, segment and market as a whole
INBX - Market capitalization of the company Inhibrx Biosciences
The Inhibrx Biosciences chart is a visualization of the platform approach in biotech. Its market cap reflects investors' faith in the company's ability to develop multiple drug candidates based on its multispecific antibody technology for the treatment of cancer and rare diseases.
INBX - Share of the company's market capitalization Inhibrx Biosciences within the market segment - General oncology therapy
Inhibrx Biosciences is a biopharmaceutical company whose market share and market capitalization reflect investor valuation of its pipeline of developments targeting various cancers and rare diseases.
Market capitalization of the market segment - General oncology therapy
Inhibrx develops complex protein therapeutics. How big is this arena? The chart below shows the pulse of the general oncology sector. Its high volatility reflects both the enormous hopes for new classes of drugs and the high risks associated with their development and clinical trials.
Market capitalization of all companies included in a broad market index - GURU.Markets
The Inhibrx Biosciences chart shows the valuation of an innovative platform for creating complex protein drugs. The company's market capitalization reflects its broad portfolio of developments in oncology and rare disease treatments. The chart's dynamics visualize how the market perceives the potential of this multidisciplinary biotech.
Book value capitalization of the company, segment and market as a whole
INBX - Book value capitalization of the company Inhibrx Biosciences
The book value of Inhibrx Biosciences, a biotech company, is its tangible assets: laboratories for developing complex protein therapeutics, platform rights, and R&D reserves. The chart below shows how this scientific and financial capital has changed.
INBX - Share of the company's book capitalization Inhibrx Biosciences within the market segment - General oncology therapy
Inhibrx Biosciences is a biopharmaceutical company whose tangible assets are research laboratories where complex protein therapeutics are developed. These R&D centers are its physical base for innovation. The chart shows the share of this specialized scientific infrastructure the company controls.
Market segment balance sheet capitalization - General oncology therapy
Inhibrx is a biotechnology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Inhibrx focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Inhibrx Biosciences' balance sheet includes laboratories and R&D centers for developing complex multispecific antibodies. The chart shows how the company built its scientific and material foundation to create a new class of therapeutic proteins.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Inhibrx Biosciences
Inhibrx is a biotech company. Its market valuation is a bet on its sophisticated platform for creating multispecific antibodies. The chart shows how investor confidence in their unique scientific approach has evolved.
Market to book capitalization ratio in a market segment - General oncology therapy
Inhibrx is a clinical-stage biopharmaceutical company with a platform for developing complex protein therapeutics. Its valuation is dependent on the success of its developments. The chart shows a high premium to its assets, reflecting the potential of its scientific platform.
Market to book capitalization ratio for the market as a whole
Inhibrx Biosciences is a clinical-stage biopharmaceutical company with a platform for developing complex protein therapeutics. Its current valuation, compared to the average, is a pure bet on the success of its scientific platform. Investors assess its potential to create a new generation of drugs, which is unrelated to its tangible assets.
Debts of the company, segment and market as a whole
INBX - Company debts Inhibrx Biosciences
Inhibrx Biosciences is developing a new class of biologics. This chart reflects its financial strategy following the company's separation. Having spun off its commercial assets into a separate company, Inhibrx now focuses on early-stage development, which requires raising equity capital to finance risky R&D projects.
Market segment debts - General oncology therapy
Inhibrx Biosciences is a clinical-stage biotech company with a diversified portfolio of drug candidates for oncology and rare diseases. This chart shows how its leverage reflects its capital requirements to fund the simultaneous advancement of multiple programs through costly clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Inhibrx Biosciences
Inhibrx is a biotech company with a broad pipeline of drug candidates for oncology and rare diseases. This chart shows how the company funds the simultaneous development of multiple projects. It reflects its financial strategy and the level of risk associated with supporting expensive research in multiple areas.
Market segment debt to market segment book capitalization - General oncology therapy
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing new classes of therapeutic antibodies. This chart shows the debt burden in the biotech sector. It is a key indicator of the company's ability to fund its diverse and expensive research in oncology and rare diseases.
Debt to book value of all companies in the market
Inhibrx Biosciences is a clinical-stage biotech company developing new classes of therapeutic antibodies. Its future depends on success in the lab. This graph of total market debt serves as an indicator of investor risk appetite, which directly impacts Inhibrx's ability to raise funds for its expensive and long-term programs.
P/E of the company, segment and market as a whole
P/E - Inhibrx Biosciences
Inhibrx Biosciences is a biotechnology company developing new classes of therapeutic antibodies for the treatment of oncology and rare diseases. This graph reflects the risks and potential associated with this innovative scientific platform. Its dynamics depend entirely on the results of clinical trials and the company's strategic decisions.
P/E of the market segment - General oncology therapy
Inhibrx Biosciences is a biotech company developing a new class of protein therapeutics for the treatment of oncology and rare diseases. Their platform enables the creation of complex, multifunctional antibodies. This chart shows the average valuation for the oncology therapeutics sector, reflecting how the market values companies with innovative technology platforms.
P/E of the market as a whole
Inhibrx is a biotech company developing a new class of protein therapeutics. Its valuation is a pure bet on the success of its scientific platform. It is not tied to the general economic cycles depicted by this chart. Inhibrx's value is determined solely by the success or failure of its clinical trials.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Inhibrx Biosciences
Inhibrx Biosciences is a biopharmaceutical company developing new classes of therapeutic antibodies. This chart reflects expectations for its scientific platform. Following the spinoff of its oncology business, the company's valuation is now focused on the potential of its drug for the treatment of alpha-1 antitrypsin deficiency and other developments.
%20P%2FE%20Inhibrx%20Biosciences&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Inhibrx-Biosciences&v=1772626029336 "Chart of the company's future (projected) P/E Inhibrx Biosciences")
Future (projected) P/E of the market segment - General oncology therapy
Inhibrx Biosciences is a biopharmaceutical company developing a new class of therapeutic antibodies for the treatment of cancer and rare diseases. This chart reflects speculative expectations for its scientific platform. Comparing its future revenue projections with the sector reveals how highly investors value its innovative approach to drug discovery.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-General-oncology-therapy&v=1772626029389 "Future (projected) P/E graph of the market segment - General oncology therapy")
Future (projected) P/E of the market as a whole
Inhibrx is a clinical-stage biopharmaceutical company developing a new class of therapeutic antibodies. Its valuation is based on the future potential of its scientific platform. This overall risk appetite curve determines how easily companies like Inhibrx can raise capital to fund their research and development.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772626029409 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Inhibrx Biosciences
Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company developing new classes of therapeutic antibodies. Its current financial performance reflects investments in its extensive pipeline. Future profits depend on successful clinical trials and partnerships with major pharmaceutical companies.
Profit of companies in the market segment - General oncology therapy
Inhibrx Biosciences is a biotech company developing a new class of therapeutic antibodies for the treatment of cancer and rare diseases. Its success depends on clinical data. The profitability chart for the general oncology sector reflects the level of competition in this field and how investors assess the potential of new technology platforms for creating breakthrough drugs.
Overall market profit
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing new classes of therapeutic antibodies for the treatment of cancer and rare diseases. Its innovative platform enables the creation of drugs with unique properties. The company's success depends on the results of clinical trials and demonstrates the potential of cutting-edge scientific research.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Inhibrx Biosciences
Inhibrx Biosciences is a biopharmaceutical company developing new classes of therapeutic antibodies. This chart reflects expectations for its clinical pipeline, particularly for its drug for a rare genetic disease. Future revenue depends on success in clinical trials.
%20profit%20of%20the%20company%20Inhibrx%20Biosciences&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Inhibrx-Biosciences&v=1772626029497 "Graph of future (projected) profit of the company Inhibrx Biosciences")
Future (predicted) profit of companies in the market segment - General oncology therapy
Inhibrx Biosciences is a biopharmaceutical company developing new classes of therapeutic antibodies. This chart reflects profitability forecasts for the biotech industry. It provides an opportunity to assess how the company's innovative scientific platform and development pipeline compare to overall sector expectations.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-General-oncology-therapy&v=1772626029521 "Graph of future (predicted) profits of companies in a market segment - General oncology therapy")
Future (predicted) profit of the market as a whole
This chart illustrates expectations for a clinical-stage biotech company. Inhibrx's revenue forecast hinges on the success of its developments in cancer and rare disease treatments. Investor expectations, as shown here, are based on the scientific potential of its platform and future clinical trial results.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772626029547 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Inhibrx Biosciences
Inhibrx is a biopharmaceutical company with a diversified pipeline. Its revenue can be volatile. This chart shows the market's aggregate assessment of the potential of its various programs. It represents a multiple of clinical data expectations rather than an estimate of current sales.
P/S market segment - General oncology therapy
Inhibrx Biosciences is a biotech company developing new classes of therapeutic antibodies for the treatment of oncology and rare diseases. Its valuation is based on the potential of its innovative platform. This chart shows the average valuation in the biotech industry, reflecting investor expectations for future revenue from Inhibrx's pipeline.
P/S of the market as a whole
Inhibrx Biosciences is a clinical-stage biotechnology company developing a new class of therapeutic antibodies for the treatment of oncology and rare diseases. This chart, showing the average revenue estimate for Inhibrx, highlights that its value is determined solely by investors' faith in its scientific platform and future clinical data.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Inhibrx Biosciences
Inhibrx Biosciences is a biotech company developing a new class of therapeutic antibodies. Its future depends on the success of clinical trials. This chart reflects investor expectations for its scientific platform. It shows the market's assessment of the likelihood of its innovative drug candidates being approved and brought to market.
%20P%2FS%20Inhibrx%20Biosciences&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Inhibrx-Biosciences&v=1772626029690 "The graph of the company's future (projected) P/S Inhibrx Biosciences")
Future (projected) P/S of the market segment - General oncology therapy
Inhibrx Biosciences is a biopharmaceutical company developing a new class of biological drugs for the treatment of oncology and rare diseases. This chart compares market expectations for its future revenue with those of other oncology companies. This valuation reflects investor confidence in its scientific platform and clinical pipeline.
%20P%2FS%20market%20segment%20graph%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-General-oncology-therapy&v=1772626029698 "Future (projected) P/S market segment graph - General oncology therapy")
Future (projected) P/S of the market as a whole
Inhibrx Biosciences is a biotech company developing a new class of therapeutic antibodies. Its future, like that of many companies in this sector, depends on the success of clinical trials. Inhibrx's potential to create breakthrough treatments is part of the overall optimism surrounding medical innovation, reflected in this chart.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772626029743 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Inhibrx Biosciences
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing new classes of protein therapies for the treatment of cancer and rare diseases. Its revenue may come from partnerships. This chart shows revenue from these deals or from future sales if its drugs are approved.
Sales of companies in the market segment - General oncology therapy
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing a new class of therapeutic antibodies for the treatment of cancer and rare diseases. Its platform enables the creation of complex protein therapeutics. This chart shows overall pharmaceutical sales, reflecting the company's ongoing search for and development of innovative approaches to treating complex diseases.
Overall market sales
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing a new class of therapeutic antibodies for the treatment of cancer and rare diseases. This overall economic activity schedule is important for Inhibrx because it impacts the availability of capital to fund lengthy and expensive clinical trials.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Inhibrx Biosciences
Inhibrx is a clinical-stage biopharmaceutical company developing new classes of therapeutic antibodies for the treatment of cancer and rare diseases. This chart reflects analysts' speculative expectations regarding the scientific potential of its platform and the likelihood of commercial success of its drug candidates.
%20sales%20of%20the%20company%20Inhibrx%20Biosciences&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Inhibrx-Biosciences&v=1772626029884 "Schedule of future (projected) sales of the company Inhibrx Biosciences")
Future (projected) sales of companies in the market segment - General oncology therapy
Inhibrx Biosciences is a biotechnology company developing new classes of therapeutic antibodies. This chart shows projected revenue for the entire biotech sector. While it reflects overall industry sentiment, for Inhibrx, the success of clinical trials for its unique protein engineering platform is crucial.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-General-oncology-therapy&v=1772626029900 "Schedule of future (projected) sales of companies in the market segment - General oncology therapy")
Future (projected) sales of the market as a whole
Inhibrx is a clinical-stage biopharmaceutical company developing a new class of protein therapies. Its value and prospects depend solely on the results of clinical trials. This graph, reflecting the overall economic situation, influences investor risk appetite and the availability of capital for biotech companies that do not yet have stable revenue but have high potential.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772626029993 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Inhibrx Biosciences
Inhibrx is a clinical-stage biotech company with a broad pipeline. The chart for such a company illustrates not profit, but rather capital management efficiency. It shows how the company spends investor funds to advance several potential drugs through costly clinical trials.
Market segment marginality - General oncology therapy
Inhibrx Biosciences is a biotech company developing a new class of therapeutic antibodies. It recently sold one of its key assets. This chart reflects its operating structure post-deal, showing how the company manages its remaining projects and capital, and allows for comparison with other clinical-stage biotechs.
Market marginality as a whole
Inhibrx Biosciences is a clinical-stage biopharmaceutical company developing new classes of therapeutic antibodies. Its future profitability depends on the success of its diverse pipeline of drug candidates. This total market return chart serves as a contrast to biotech, where scientific innovation and the potential to treat a wide range of diseases determine long-term value.
Employees in the company, segment and market as a whole
Number of employees in the company Inhibrx Biosciences
Inhibrx is a biotech company developing a new class of therapeutic antibodies. This graph shows a team of scientists working on several programs. Headcount dynamics may reflect strategic decisions, such as spinning off one asset into a separate company, which allows for focused resources.
Share of the company's employees Inhibrx Biosciences within the market segment - General oncology therapy
This figure reflects Inhibrx Biosciences' scientific approach. The company's oncology team is focused on developing a new class of protein therapeutics for the treatment of cancer and rare diseases. This team of scientists creates complex protein molecules capable of performing multiple functions simultaneously, increasing the effectiveness of treatments.
Number of employees in the market segment - General oncology therapy
Inhibrx Biosciences is a biopharmaceutical company developing a new class of protein therapeutics. Their innovative platform enables the creation of more effective drugs. This graph demonstrates that the biotech industry is constantly exploring new approaches to drug development, which maintains a high demand for bioengineering scientists.
Number of employees in the market as a whole
Inhibrx Biosciences, Inc. is a clinical-stage biotechnology company. Its value is determined by the potential of its scientific developments. This total earnings schedule is unrelated to its activities, which are focused on developing a new class of protein therapeutics.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Inhibrx Biosciences (INBX)
Inhibrx Biosciences is a biotech company developing new classes of therapeutic antibodies. This chart demonstrates the high valuation of its scientific platform. The astronomical market capitalization per research employee reflects investor expectations for its innovative developments, not current financial results.
%20of%20the%20company%20Inhibrx%20Biosciences%20(INBX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Inhibrx-Biosciences-INBX&v=1772626030499 "Chart of market capitalization per employee (in thousands of dollars) of the company Inhibrx Biosciences (INBX)")
Market capitalization per employee (in thousands of dollars) in the market segment - General oncology therapy
Inhibrx Biosciences is developing a new class of protein therapeutics. As with any biotech venture, its value is a reflection of its scientific potential. The chart illustrates the enormous value the market places on the company's innovative platform and its ability to create unique drugs for the treatment of complex diseases.
%20by%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-General-oncology-therapy&v=1772626030532 "Market capitalization per employee (in thousands of dollars) by market segment - General oncology therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Inhibrx Biosciences is a biotech company developing a new class of therapeutic antibodies. This chart shows a high salary per employee, which is typical for R&D companies. The value is determined by the potential of its scientific platform and its pipeline of early-stage drug candidates.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772626030589 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Inhibrx Biosciences (INBX)
Inhibrx Biosciences (INBX) is a clinical-stage biotech company developing antibodies for the treatment of cancer and rare diseases. The company is not commercially profitable. This chart shows the net loss (R&D costs) per scientist working on the development of a new drug.
%20Chart%20Inhibrx%20Biosciences%20(INBX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Inhibrx-Biosciences-INBX&v=1772626030623 "Company Profit Per Employee (in thousands of dollars) Chart Inhibrx Biosciences (INBX)")
Profit per employee (in thousands of dollars) in the market segment - General oncology therapy
Inhibrx Biosciences is a biotech company developing new classes of therapeutic antibodies. It focuses on oncology and rare diseases. This chart shows the loss per employee during the R&D phase. It serves as a benchmark for assessing how intensively the company invests in its scientists to advance its unique, yet risky, platform compared to other biotech companies.
%20in%20the%20market%20segment%20-%20General%20oncology%20therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-General-oncology-therapy&v=1772626030630 "Chart of profit per employee (in thousands of dollars) in the market segment - General oncology therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Inhibrx Biosciences (INBX) is a clinical-stage biotech company developing new classes of therapeutic antibodies for the treatment of cancer and rare diseases. Like other R&D biotech companies, this chart shows the company's per-employee loss. It reflects how much the company spends on each scientist in the lab and clinical trials trying to prove the efficacy of its drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772626030637 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Inhibrx Biosciences (INBX)
Inhibrx is a clinical-stage biotech company developing new classes of therapeutic antibodies. This chart reflects the company's activities, which are focused on research. Revenue per employee is minimal and depends on partnerships with major pharmaceutical companies.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Inhibrx-Biosciences-INBX&v=1772626030667 "Sales chart per company employee Inhibrx Biosciences (INBX)")
Sales per employee in the market segment - General oncology therapy
Inhibrx is a biotech company developing a broad range of therapeutic antibodies. This chart shows the average revenue per employee in the segment. For a company with an R&D platform, this compares to benchmark productivity in the sector, where revenue often depends on development milestones and partnerships.
Sales per employee for the market as a whole
Inhibrx is a clinical-stage biotech company developing new classes of therapeutic antibodies. They have no commercial products. This figure would be zero. Their entire staff (scientists) is focused on research and development of new drugs, and funding comes from investors.
Short shares by company, segment and market as a whole
Shares shorted by company Inhibrx Biosciences (INBX)
Inhibrx is a biotech company. The bearish sentiment seen in this chart is a standard bet against R&D biotech companies. Bears point to the lack of revenue, high cash burn, and low likelihood of their rare disease treatment candidates successfully completing clinical trials.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Inhibrx-Biosciences-INBX&v=1772626030744 "Short Shares Chart for the Company Inhibrx Biosciences (INBX)")
Shares shorted by market segment - General oncology therapy
Inhibrx is a biotech company developing new classes of therapeutic proteins (antibodies) for the treatment of oncology and rare diseases. This chart reflects the overall sentiment in the sector. It reflects the high investor skepticism toward biotech companies whose platforms have not yet proven their worth with approved drugs.
Shares shorted by the overall market
Inhibrx Biosciences (INBX) is a clinical-stage biotech with a broad pipeline. Its value is based on the likelihood of success for multiple drugs. This chart is an indicator of risk aversion. When fear dominates, investors are reluctant to analyze complex scientific portfolios and prefer to simply sell off the entire speculative sector.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Inhibrx Biosciences (INBX)
Inhibrx is a biotech company. This chart measures the extremes of speculative sentiment. It shows when the stock is "overheated" (overbought) on positive lab news or "oversold" (bottomed out) amid a general cooling in the biotech sector or R&D failures.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Inhibrx-Biosciences-INBX&v=1772626030839 "RSI 14 indicator chart for the company's stock Inhibrx Biosciences (INBX)")
RSI 14 Market Segment - General oncology therapy
Inhibrx is a clinical-stage biopharmaceutical company developing new classes of therapeutic antibodies. Their platform enables the creation of complex protein drugs for oncology and rare diseases. This chart reflects the overall sentiment in the biotech sector, helping to assess how the market views this speculative industry as a whole.
RSI 14 for the overall market
Inhibrx (INBX) is a biotech company. Like everything in its sector, it's critically dependent on this chart. Market euphoria is an easy way to raise hundreds of millions of dollars for research. Market panic is the risk of running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast INBX (Inhibrx Biosciences)
Inhibrx (INBX) is a biotech company developing new classes of therapeutic proteins for the treatment of oncology and rare diseases. This chart shows the average 12-month forecast. It reflects analysts' assessment of the company's scientific platform and the potential of its lead candidates in clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-INBX-Inhibrx-Biosciences&v=1772626030978 "A chart showing analyst consensus forecasts for the expected stock price. INBX (Inhibrx Biosciences)")
The difference between the consensus estimate and the actual stock price INBX (Inhibrx Biosciences)
Inhibrx (INBX) is a biotech company whose key bet is INBRX-101, a drug for the treatment of a rare genetic lung disease (AATD). This is an R&D bet on a single asset. This chart shows the difference between the consensus estimate and the price, reflecting analysts' confidence in the success of this blockbuster drug.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-INBX-Inhibrx-Biosciences&v=1772626031073 "A chart showing the difference between the consensus forecast and the actual stock price. INBX (Inhibrx Biosciences)")
Analyst consensus forecast for stock prices by market segment - General oncology therapy
Inhibrx is a biotech company using its platform to create complex protein therapeutics, including those for the treatment of alpha-1 antitrypsin deficiency. This chart shows analysts' overall expectations for the general oncology/pharma sector. It reflects the experts' confidence in the company's R&D pipeline.
Analysts' consensus forecast for the overall market share price
Inhibrx is a biotech company with a diversified portfolio developing treatments for cancer and rare diseases. Their strategy is to create "multispecific" antibodies. This chart shows overall market sentiment. For Inhibrx, as an R&D company, it's important to understand how overall risk appetite (sentiment) influences the valuation of their broad, yet risky, portfolio. (350)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Inhibrx Biosciences
Inhibrx is a clinical-stage biotech company specializing in the development of smart antibodies. They are focused on rare diseases such as AATD (a lung disease). This graph represents pure R&D investment. It likely reflects the market's confidence in their scientific platform and, most importantly, their clinical data for the treatment of AATD.
AKIMA Market Segment Index - General oncology therapy
Inhibrx (INBX) is a clinical-stage biotech focused on oncology and immunology; the company is developing a portfolio of innovative antibodies (including the AATD product sold to Sanofi). This summary metric evaluates R&D. The graph shows the average value for the segment. This is a benchmark: how does this R&D platform (INBX) differentiate it from the average pharma company?
The AKIM Index for the overall market
Inhibrx Biosciences is a clinical-stage biotech company developing biologics for the treatment of cancer and rare diseases. This chart, which reflects the market average, is an indicator of risk appetite. It provides a macro backdrop that is critical for funding and assessing the prospects of this scientific platform.
